Revolution Medicines, Inc. Accrued Expenses And Other Current Liabilities decreased by 8.1% to $192.45M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 96.2%, from $98.11M to $192.45M. Over 5 years (FY 2020 to FY 2025), Accrued Expenses And Other Current Liabilities shows an upward trend with a 62.0% CAGR.
Rising levels may indicate growing operational activity or delayed billing cycles, while falling levels suggest a reduction in near-term operational commitments.
This encompasses obligations for expenses that have been incurred but not yet invoiced or paid by the reporting date. It...
Common in all companies; biotech firms often have significant accruals related to clinical trial activities.
current_liabilities_accrued_expenses_and_other_current_l_f358d2| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $22.10M | $23.78M | $27.72M | $25.52M | $33.76M | $32.19M | $29.45M | $27.37M | $42.56M | $50.16M | $74.69M | $53.18M | $67.68M | $78.01M | $96.62M | $98.11M | $114.69M | $154.45M | $209.34M | $192.45M |
| QoQ Change | — | +7.6% | +16.6% | -7.9% | +32.3% | -4.7% | -8.5% | -7.1% | +55.5% | +17.9% | +48.9% | -28.8% | +27.3% | +15.3% | +23.8% | +1.6% | +16.9% | +34.7% | +35.5% | -8.1% |
| YoY Change | — | — | — | — | +52.7% | +35.4% | +6.2% | +7.2% | +26.1% | +55.8% | +153.7% | +94.3% | +59.0% | +55.5% | +29.3% | +84.5% | +69.4% | +98.0% | +116.7% | +96.2% |